



## **Poster illustrating latest promising TNF $\alpha$ Kinoid clinical data to be presented at DDW 2010 in New Orleans**

**Paris, April 21 2010** – Neovacs (Alternext Paris: ALNEV) announced today that a poster sharing the latest clinical results achieved with its TNF $\alpha$  Kinoid immunotherapy in patients with Crohn's Disease will be presented at Digestive Disease Week. [DDW 2010](#) will take place from May 1<sup>st</sup> to 5<sup>th</sup> in New Orleans.

The poster presentation is part of the Tuesday May 4<sup>th</sup> session, with the theme of "IBD: Controlled Clinical Trials in Humans", in Hall F of the Ernest N. Morial Convention Center. The poster is titled "Active therapeutic immunization against TNF with a TNF Kinoid in Crohn's disease patients: A Phase 1-2 Study." The lead author of the poster is Professor Gerhard Rogler, of the Department of Gastroenterology and Hepatology of the University Hospital, Zurich, and one of the clinical investigators on the trial.

Neovacs' TNF $\alpha$  Kinoid is in clinical development for Crohn's disease and rheumatoid arthritis indications.

### **About Neovacs**

Neovacs is a biotechnology company focused on an active immunotherapy technology platform with applications in autoimmune diseases and other chronic conditions. It was founded as a spin-off from Pierre & Marie Curie University in Paris by Professor Daniel Zagury, MD, one of the world's leading immunologists.

Neovacs' portfolio currently consists of drug 3 candidates: TNF $\alpha$ -K, IFN $\alpha$ -K and VEGF-K. The company's lead immunotherapy program, TNF $\alpha$ -K targets TNF $\alpha$ -mediated chronic inflammatory diseases. It is in a Phase I/II clinical trial in Crohn's Disease patients, and a Phase II trial in rheumatoid arthritis patients. This clinical study is also the focus of a collaboration with the diagnostics company BMD, with the goal of developing theranostic tools for personalized care. At the end of 2008, TNF-K was selected by Thomson Reuters as the most promising drug to be entering Phase II clinical trials.

The company second product candidate, IFN $\alpha$  K, an immunotherapy targeting interferon alpha (IFN $\alpha$ ), in lupus patients is entering Phase I/II for lupus.

The company's R&D has generated a broad patent estate.

For more information, visit the Neovacs web site at [www.neovacs.com](http://www.neovacs.com).

## **About DDW**

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. It is jointly sponsored by the American Association for the Study of Liver Diseases, the AGA Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract. For more information, visit [www.ddw.org](http://www.ddw.org).

## **Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Neovacs in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers ("AMF") granted its visa no. 10-085 on April 8, 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

## **Press contacts**

### **Alize RP**

Caroline Carmagnol  
+33 (0) 6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)  
Charles Catherinot  
+ 33 (0) 1 42 68 86 40  
[charles@alizerp.com](mailto:charles@alizerp.com)

### **Neovacs**

Piers Whitehead  
+33 (0) 1 53 10 93 08  
[pwhitehead@neovacs.com](mailto:pwhitehead@neovacs.com)